The Food and Drug Administration (FDA) has recently approved Keytruda (pembrolizumab) plus chemoradiotherapy for the treatment of patients with stages 3 to 4A cervical cancer.
The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.